ArticleAnnals of hematology2025
Paediatric lymphoblastic lymphoma: a national review of 20 years of clinical and biological data in Ireland.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Small biopsy diagnosis of anterior mediastinal masses: histologic, immunohistochemical, and molecular considerations.Mediastinum (Hong Kong, China) · 2026Review
- Outcomes of T-cell lymphoblastic lymphoma in children and adolescents treated with Dana-Farber Cancer Institute Childhood ALL Consortium protocols.Frontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphoblastic lymphoma (LBL) is a rare, aggressive malignancy comprising T-cell (T-LBL) and B-cell (B-LBL) subtypes. While outcomes for LBL have improved, comprehensive national data on clinical and biological features remain limited. We conducted a retrospective review of children and adolescents with LBL in Ireland over 20 years (2004-2023). Data on demographics, clinical presentation, tumour characterization, treatment protocols, and outcomes were analysed. The cohort included 52 patients: 79% with T-LBL and 21% with B-LBL. T-LBL cases predominantly affected males (2.2:1) and presented with advanced disease, including mediastinal masses (98%) and high lactate dehydrogenase levels. B-LBL cases had a female predominance (0.4:1) and localized disease (82%). Survival outcomes were excellent for B-LBL, with 5-year event-free survival (EFS) and overall survival (OS) of 100%. For T-LBL, 5-year EFS and OS were 85%. Relapsed/refractory disease occurred in 4% (T-LBL only). Genetic, Minimal Disseminated Disease and Minimal Residual Disease analyses were limited. LBL outcomes in Ireland align with international reports, highlighting favourable survival but underscoring the need for improved risk stratification and genetic profiling, particularly for T-LBL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.